OBJECTIVE: To probe into the clinical efficacy of three different empirical anti-infection programs in the treatment of patients with community-acquired pneumonia and its effects on inflammatory state

so as to provide reference for the optimized treatment for community-acquired pneumonia. METHODS: Totally 240 patients with community-acquired pneumonia admitted into Central Hospital Affiliated to Shenyang Medical College in 2018 were extracted to be divided into the group A

group B and group C via different treatment programs

with 80 cases in each group. The group A was treated with levofloxacin

the group B was given piperacillin sulbactam sodium

while the group C received cefodizime sodium. The clinical efficacy

length of stay

incidence of adverse drug reactions and levels of inflammatory factors [hypersensitive C-reactive protein（ hs-CRP）

procalcitonin（ PCT） ] before and after treatment of three groups were observed. RESULTS: The total effective rate of group A was 97. 50%（ 78/80）

significantly higher than that of group B [91. 25%（ 73/80） ] and group C [88. 75%（ 71/80） ]

the difference was statistically significant（ P<0. 05）; and there was no significant difference between group B and group C（ P > 0. 05）.There was no significant difference in the length of stay among three groups（ P>0. 05）. The incidence of adverse drug reactions in group A

group B and group C was 2. 50%（ 2/80）

2. 50%（ 2/80） and 5. 00%（ 4/80）

respectively

the adverse drug reactions of three groups were mild

without any significant difference（ P > 0. 05）. After treatment

the levels of hs-CRP and PCT in three groups were significantly improved compared with those before treatment

and the data in group A were significantly lower than those in groups B and group C

the differences were statistically significant（ P< 0. 05）. CONCLUSIONS: Levofloxacin is more effective in empirical treatment of community-acquired pneumonia and can significantly improve patient’s inflammatory state.